The AI trade takes its first real hit: Broadcom’s soft chip outlook erases more than $250bn and drags the Nasdaq and S&P off record highs · Israel and Lebanon agree a ceasefire even as the US and Iran trade fresh strikes, and the Republican-led House votes to curb Trump’s war powers · the Fed turns more hawkish — Logan flags a possible rate rise this year as the Beige Book shows firmer inflation · the IPO machine rolls on, with JPMorgan, Morgan Stanley and Goldman lining up behind SpaceX and Anthropic.
Europe/Rome 06:00 · Markets open · pre-US-open · Consolidating · AI trade tested off records
Levels below are the Bloomberg Europe live ticker read at ~06:00 Rome. US indices reflect the latest close — the session that slipped from record highs as Broadcom’s miss hit the AI-chip complex — while FTSE, FX and commodities are live. The week’s decisive data lands tomorrow: the US May jobs report on Friday (5 June) now meets a Fed that is suddenly sounding less dovish after Dallas Fed’s Logan flagged a possible rate rise.
Top of the morning
Israel and Lebanon agree a ceasefire — even as the US and Iran trade fresh strikes
Bloomberg’s lead has Israel and Lebanon reaching a conditional truce, contingent on Hezbollah standing down, days after a Trump–Netanyahu phone call — a de-escalation on one front. The wider conflict stays live, though: the US and Iran exchanged new military strikes overnight, and in a striking domestic twist the Republican-led House voted to halt the Iran war, an open rebuke of Trump’s war powers. Crude held a premium near $95 while gold’s haven bid eased slightly as the Lebanon front cooled.
Broadcom’s miss knocks the AI trade off its record
Shares in Broadcom slid after a disappointing AI-chip revenue outlook — FT alerts put the market-value loss above $250bn, with the stock down as much as 15% after hours — dragging the Nasdaq and S&P 500 back from all-time highs. The counter-signal is structural: TSMC’s CEO warned chip supply won’t meet AI-fuelled demand for years, framing the paradox of intact long-term demand against near-term expectations that had run hot. CrowdStrike’s soft guidance added to a more cautious tech tape.
Europe’s big three sketch a plan to bring Putin to Ukraine talks
Germany, France and the UK are drawing up an approach to engage Vladimir Putin directly, with the allies seeing a shift in momentum that strengthens Zelenskyy’s position. In parallel, Washington has told European partners to add more aircraft and vessels as it draws down its own presence — sharpening the burden-shift debate and echoing recent talk of wider US nuclear-bomber basing in Europe.
The IPO machine accelerates: JPMorgan to pitch SpaceX; Anthropic taps Wall Street
A Bloomberg exclusive has Jamie Dimon set to pitch JPMorgan’s ultra-rich clients on the SpaceX IPO — likely the largest market debut ever — while Anthropic has picked Morgan Stanley and Goldman Sachs to lead its own listing. The plumbing is ready for the supply: a Vanguard fund became the first ETF to top $1tn in assets, a marker of how much passive money stands ready to absorb the issuance wave.
The Fed turns more hawkish into Friday’s payrolls
Dallas Fed’s Lorie Logan said the central bank may need to raise interest rates this year, and the Beige Book described steady employment alongside firmer inflation — a combination that nudged the US 10-year to ~4.48% and trimmed gold. It resets the stakes for tomorrow’s US May jobs report, which now lands against a Fed sounding readier to hold, or even tighten, than to cut.
Private-credit warning lights blink again; Bitcoin slides to pre-Iran lows
Credit titans warned of a coming shakeout in deals that “don’t make sense,” and separate reporting describes retail investors edging toward the exits across private credit — the clearest persistent crack under an otherwise orderly tape. Risk appetite cooled elsewhere too: Bitcoin fell to its lowest since before the Iran conflict as the crypto slide extended. A watch item for the credit cycle, not yet a systemic event.
Health watch: Ebola widens in DR Congo; a screwworm scare in US cattle
FT and Bloomberg both flag a widening Ebola outbreak (the Bundibugyo strain) spreading to new areas of the DR Congo, with one infected person known to have travelled to the UAE before falling ill — a reminder that under-the-radar threats can escalate, and that the vaccine response is now the variable to watch. Separately, a deadly screwworm parasite found in the US threatens the cattle herd. Clinically and biosecurity-relevant reading for the medical sector.
FT portfolio signal · tied to your holdings
What FT flagged for your book
Macro / regime read. Yesterday’s theme was “respect the froth”; this morning the froth took its first real poke. The myFT cluster still skews bullish on supply — Goldman’s chief seeing more greed than fear, an Unhedged piece on the “equity tap” with more to come, ~$675bn of fresh tech equity on offer, a Vanguard fund topping $1tn, and a “mammoth” IPO year — but the counterweight has arrived in the form of Broadcom’s miss, the first AI-earnings stumble to actually dent the tape. Two cautions the dashboard cares about are now both live: an AI-earnings / valuation test (Broadcom −15% after hours, >$250bn erased) and a firmer-rates backdrop (Logan flagging a possible hike, Beige Book inflation, 10y ~4.48%), with the private-credit crack still present. The war-chest deployment rules stay dormant — this is a wobble and a regime tilt, not a severe trigger.
Broadcom (shelf single-name hit — the key one). The morning’s marquee name on your shelf: a myFT alert puts the market-cap loss above $250bn with shares down ~15% after hours on a disappointing revenue forecast. Read-through: a direct holding is the epicentre of the AI-chip repricing. TSMC’s warning that supply won’t meet AI demand for years supports the long-term thesis, but near-term the miss dominates — the watch is whether this is a single-name stumble or the start of a broader AI-capex earnings test.
Alphabet (shelf single-name hit). Alphabet upsized its record equity raise to $85bn — its first stock offering in more than two decades — to fund AI spending. Real dilution, but it bankrolls the build-out behind the thesis; the signal is conviction in the cycle, with capital absorption the watch.
Microsoft (shelf single-name hit). A myFT Microsoft alert has the company squaring up to Anthropic with new model releases, AI chief Mustafa Suleyman framing the focus as products for business users — MSFT pressing its enterprise-AI / Azure edge as foundation-model rivalry intensifies.
Semiconductors / AI capex (theme hits). Chris Miller on the fragile US–China tech truce, a “Japanese hardware stocks are having a moment” piece, and SpaceX’s $55bn Terafab AI-chip plant all bear on the picks-and-shovels case behind your ASML, Broadcom, Microsoft/Azure, Alphabet shelf — with supply-chain and geopolitical risk the offset to respect, and Broadcom a live reminder that the bar is now high.
Pharma / health colour (no single-name hit). The pharma and health alerts skewed to the widening Ebola outbreak and the vaccine race — public-health and sector context only, with no direct read on Novo Nordisk, Eli Lilly, Vertex, UnitedHealth, Thermo Fisher or Intuitive Surgical.
Shelf single-names: today’s live alerts are Broadcom, Alphabet and Microsoft. No GLP-1 / Novo Nordisk / Eli Lilly / Vertex / UnitedHealth / Intuitive / Visa / Mastercard / Berkshire single-name FT items in the window. (Name-level alerts only surface here once FT routes them to this Gmail — see the iCloud→Gmail forwarding note if they stay sparse.)
Net: the AI trade just took its first real poke (Broadcom), even as the capex-financing wave keeps swelling (Alphabet $85bn, SpaceX/Anthropic IPOs) and the Fed turns more hawkish. Regime tilting from risk-on-froth toward consolidation — watch AI earnings, credit and rates. Not a deploy trigger. Friday’s US payrolls is the swing event.
Markets snapshot
Bloomberg Europe live ticker at ~06:00 Rome. US indices are the latest close (slipped from records on Broadcom); FTSE, FX and commodities live. Daily % changes as shown on the ticker.
Instrument
Last
Change / context
S&P 500
7,553.68
−0.74% · off record on Broadcom miss
Nasdaq
26,853.97
−0.89% · AI chips lead the pullback
Bloomberg 500
2,732.45
−0.77%
FTSE 100
10,332.30
−0.40% · softer with global risk
US 10-year Treasury
4.48%
yields firmer · Logan hawkish, Beige Book inflation
Figures transcribed from the Bloomberg Europe “Top Securities” ticker; FX shown to two decimals as on the ticker. Equity direction confirmed against the “stocks fall from record on Broadcom” market lead and the prior session’s closing levels.
Global markets & macro
The AI trade met its first real test. Broadcom’s disappointing chip outlook erased more than $250bn of market value and sent the stock down as much as 15% after hours, dragging the Nasdaq (−0.89%) and S&P 500 (−0.74%) back from record highs — the “more greed than fear” tape finally meeting a stumble. Yet the AI-financing wave keeps building around it: Alphabet upsized its equity raise to $85bn, Anthropic lined up Morgan Stanley and Goldman for its IPO, JPMorgan is preparing to pitch SpaceX to its ultra-rich clients, and Vanguard’s first $1tn ETF underscores how much passive money is ready to absorb the supply. TSMC’s warning that chip supply won’t meet AI demand for years frames the paradox neatly — structural demand intact, near-term expectations stretched — while CrowdStrike’s soft guidance and Bitcoin’s slide to pre-Iran lows round out a more cautious risk tape.
Rates turned the other, firmer way, and that is the morning’s quieter shift. Dallas Fed’s Lorie Logan said the Fed may need to raise rates this year, and the Beige Book showed steady jobs but firmer inflation, nudging the 10-year to ~4.48% and trimming gold’s haven bid to ~$4,490. FX stayed quiet — the euro near 1.16 and sterling around 1.34, both little changed. Private credit remains the cycle’s soft spot: credit titans warned of a shakeout in deals that don’t make sense, and retail money is starting to edge out of the asset class. With a Fed that suddenly sounds less dovish, Friday’s US May payrolls becomes the week’s decisive print — a hot number would harden the hawkish turn, a soft one would test it.
Geopolitics & world news
The Middle East delivered mixed signals. Israel and Lebanon agreed a conditional ceasefire — a de-escalation on the Hezbollah front, contingent on the militia standing down and arriving days after a Trump–Netanyahu call. But the broader conflict stayed live: the US and Iran traded fresh strikes overnight, and in a notable domestic check the Republican-led House voted to halt the Iran war, rebuking Trump’s handling of it. Markets read the balance through commodities — crude holding a premium near $95 on lingering Strait of Hormuz risk, while gold’s safe-haven bid eased a touch as one front cooled. A Bloomberg feature on the “Iran shock” accelerating Asia’s and Europe’s energy transition is the longer-run thread worth keeping in view.
Europe’s security board is shifting too. Germany, France and the UK are sketching a plan to engage Putin directly in Ukraine talks, sensing a momentum shift that strengthens Zelenskyy’s hand, even as Washington tells European allies to add aircraft and vessels as it draws down — sharpening the burden-shift debate and echoing recent talk of wider US nuclear-bomber basing on the continent. For the medical reader, the standout is clinical and biosecurity-flavoured: the Ebola outbreak (Bundibugyo strain) is widening across the DR Congo with a cross-border travel scare reaching the UAE, putting the vaccine response in focus, while a deadly screwworm parasite found in US cattle is a reminder of zoonotic risk to the food chain. Both are public-health items worth tracking, for healthcare and for the investment landscape around it.
Clinical desk · NEJM current issue (4 June 2026)
This week in the New England Journal
A deeper read of the issue’s practice-relevant trials, with the numbers that matter at the bedside.
Cardiology — LAAC moves toward the anticoagulation-eligible
CHAMPION-AF randomised 3,000 AF patients who were suitable NOAC candidates (mean CHA₂DS₂-VASc 3.5) to a Watchman Flx device or a NOAC. At 3 years the composite of CV death, stroke or systemic embolism was 5.7% vs 4.8% (difference 0.9 pp, 95% CI −0.8 to 2.6) — meeting noninferiority — while non–procedure-related bleeding was roughly halved (10.9% vs 19.0%, HR 0.55), a superiority win. Caveats worth holding onto: strokes were numerically higher with the device (3.6% vs 2.5%; ischaemic stroke/systemic embolism ~0.3%/yr more), the highest-risk patients (CHA₂DS₂-VASc ≥5) were under-represented, only one device was studied, and the trial was industry-funded with an absolute (not relative) noninferiority margin. The companion editorial asks directly whether indications should now widen. Practical read: a stronger case for LAAC as a shared-decision option in bleeding-averse but anticoagulation-eligible AF — the 5-year stroke data will be the tell.
Critical care — high-flow oxygen: fewer intubations, same mortality
SOHO (42 French ICUs, 1,110 patients with P/F ≤200) found day-28 mortality identical at 14.6% vs 14.6% (P=0.98) for high-flow nasal oxygen vs standard oxygen. Intubation by day 28 was lower with high-flow (42.4% vs 48.4%, difference −5.9 pp), but serious events during spontaneous breathing (cardiac arrest or pneumothorax) were numerically more frequent (2.3% vs 1.1%). Read: this tempers the mortality rationale for HFNC; the intubation benefit persists, so the case stays individualised rather than universal.
Oncology — a step-change in pancreatic cancer
Daraxonrasib (RASolute 302). Phase 3, 500 patients with previously treated metastatic PDAC (92% RAS G12); this oral RAS(ON) inhibitor roughly doubled median overall survival vs chemotherapy (13.2 vs 6.6 months, HR 0.40, P<0.001) and improved PFS (7.3 vs 3.5 months, HR 0.45). Grade ≥3 events were actually lower than chemo (61.8% vs 69.6%) and treatment-related discontinuations far lower (1.2% vs 11.2%). In a disease where median survival is under a year, this is the standout result of the issue.
Perioperative apalutamide (PROTEUS). Phase 3, 2,109 patients, ADT ± apalutamide around radical prostatectomy. Pathological complete response / minimal residual disease rose to 8.9% vs 1.0% (OR 10.2) and 5-year metastasis-free survival to 78.2% vs 73.5% (HR 0.80, P=0.02); grade 3/4 events were higher (39.6% vs 31%, mostly rash). The first practice-changing neoadjuvant signal in prostate cancer — though the absolute MFS gain (~4.7 pp) is modest, and the editorial’s “watershed” framing is about direction more than magnitude.
Also: all-oral decitabine–cedazuridine + venetoclax gave complete responses in ~47% of newly diagnosed AML; adjuvant selpercatinib lengthened event-free survival in RET fusion–positive early-stage NSCLC.
AI in the clinic (your beat)
The governance layer is catching up to deployment. A Perspective on ambient AI documentation maps the recording-consent problem — two-party-consent states, where audio is transmitted, and the patchwork of state law that every ambient-scribe pilot now runs into — alongside an NEJM AI review on large language models in informed consent (opportunities vs thin evidence), a privacy analysis of AI scribes, and a behavioural-health letter warning that chatbot empathy can outpace accuracy. Collectively: useful tools, but consent, privacy and monitoring are the gating issues, not raw capability.
Infectious disease — ties to this morning’s Ebola thread
A correspondence characterises the 2025 Sudan virus (an ebolavirus) outbreak in Uganda, and another reports that IV artesunate still performed acceptably in children with partially artemisinin-resistant severe malaria (PfK13 mutations) — reassuring that parenteral artesunate remains usable. Directly relevant context as the markets pages flag a widening DR Congo Ebola outbreak with a cross-border travel scare.
Briefly noted
Obexelimab cut flares and glucocorticoid use in a phase-3 trial in IgG4-related disease; secukinumab hit its mark in relapsed polymyalgia rheumatica but missed in giant-cell arteritis; dual CAR T-cell desensitisation enabled kidney transplantation in two highly HLA-sensitised candidates; and a clinical-practice review distils what actually moves childhood vaccine hesitancy (clinician recommendation, presumptive framing, empathy).
Read from your open NEJM tab via Control Chrome — the current issue plus the full CHAMPION-AF, SOHO, RASolute 302 and PROTEUS abstracts. Figures summarised in original prose under copyright caution — not reproductions, and not medical advice for any individual patient.
Today & week ahead (CET)
Thu 4US weekly jobless claims · Challenger job cuts · euro-area data — the payrolls warm-up, now read through a more hawkish Fed lens after Logan
Fri 5US May jobs report — payrolls and unemployment, the week’s marquee print, landing against a Fed sounding readier to hold or hike · Bloomberg Money launches
WatchAI-earnings test after Broadcom · chip-supply signals (TSMC) · private-credit redemptions & retail exits · oil on Iran–Hormuz headlines · Bitcoin’s slide · Fed rate-path repricing after Logan